CytomX TherapeuticsCTMX -1.51%36 Quick Ratio is 10.38 as of Mar. 2026, which is 178% above its 10-year median of 3.74. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,417 Biotechnology companies, CytomX Therapeutics ranks better than 79.82% on this metric.
CytomX Therapeutics has a quick ratio of 10.38. It generally indicates good short-term financial strength.
The historical rank and industry rank for CytomX Therapeutics's Quick Ratio or its related term are showing as below:
CTMX'
s Quick Ratio Range Over the Past 10 Years
Min: 1 Med: 3.74 Max: 10.38
Current: 10.38
During the past 13 years, CytomX Therapeutics's highest Quick Ratio was 10.38. The lowest was 1.00. And the median was 3.74.
CTMX's Quick Ratio is ranked better than 79.82% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs CTMX: 10.38
CytomX Therapeutics (NAS:CTMX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
CytomX Therapeutics Quick Ratio Related Terms
CytomX Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for CytomX Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CytomX Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytomX Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where CytomX Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
CytomX Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytomX Therapeutics (CTMX) has a Quick Ratio of 10.38 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on CytomX Therapeutics and its competitors. This is 178% above median its historical median of 3.74. Over the past decade, CytomX Therapeutics' Quick Ratio has ranged from 1.00 to 10.38. According to the industry distribution chart, CytomX Therapeutics ranks #286 out of 1417 companies in the Biotechnology industry, placing it in the top 20.2%.
Is CytomX Therapeutics' Quick Ratio too high?
CytomX Therapeutics' current Quick Ratio of 10.38 is 178% above median its 10-year median of 3.74. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.38. The Biotechnology industry median Quick Ratio is 3.60. CytomX Therapeutics' value of 10.38 is 188.3% above this industry median. Based on the distribution chart, CytomX Therapeutics ranks #286 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Quick Ratio compare to SMNR and AURA?
According to the Biotechnology industry distribution chart, CytomX Therapeutics ranks #286 out of 1417 companies for Quick Ratio. This places CytomX Therapeutics in the top 20% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. CytomX Therapeutics' value of 10.38 is 188.3% above this benchmark. Historically, CytomX Therapeutics' own Quick Ratio has ranged from 1.00 to 10.38 over the past decade. While the company's 10-year median is 3.74 vs. the industry median of 3.60, CytomX Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytomX Therapeutics's current Quick Ratio of 10.38 is 188.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on CytomX Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytomX Therapeutics's current Quick Ratio is 10.38, which is 178% above median its own 10-year median of 3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.27 — trading 1067.9% above its estimated fair value. The current Quick Ratio is 10.38, which is 178% above median its 10-year median of 3.74 and 188.3% above the Biotechnology industry median of 3.60. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Quick Ratio is 10.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CytomX Therapeutics (CTMX) Overvalued in 2026?
Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued.
The current stock price of $3.27 is trading 1067.9% above its estimated GF Value™ of $0.28.
GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.
Key valuation signals for CTMX:
Quick Ratio: 10.38 (178% above median its 10-year median of 3.74)
GF Value™: $0.28 vs. price of $3.27 (1067.9% above fair value)
Industry Position: 188.3% above the Biotechnology median (#286 of 1417)
No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score
Get the complete analysis for CTMX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTMX has been successfully added to your 
